Drug Profile

ARX 1796

Alternative Names: ARX-1796

Latest Information Update: 28 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arixa Pharmaceuticals
Developer Pfizer
Class Antibacterials
Mechanism of Action Beta lactamase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Gram-negative infections

Most Recent Events

28 Nov 2023 No recent reports of development identified for phase-I development in Gram-negative-infections in USA (PO)
22 Oct 2020 Arixa Pharmaceuticals has patent protection for prodrugs covering broad composition of matter patent (Arixa Pharmaceuticals pipeline, October 2020)
22 Oct 2020 Phase-I clinical trials in Gram-negative infections in USA (PO) prior to October 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com